Skip to main content

OPtimizing TArgets and Therapeutics In high risk and refractOry Multiple Myeloma

Objetivo

Multiple Myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of the OPTATIO consortium to seek out novel strategies for the development of novel diagnostic and therapeutic options. The MM pathogenesis involves not only genetic changes within the tumour cells but also the emergence of supportive conditions by the bone marrow microenvironment (BMM). To target the essential components of this support system, it is the goal of the project to establish preclinical in vitro and in vivo models of MM that include functionally relevant elements of the BMM. The OPTATIO consortium will therefore analyse clinical data to correlate the presence of particular MM-BMM interactions with the pathogenesis of MM, with its intrinsic therapy resistance as well as with disease relapse due to the development of acquired drug resistance. These correlative data will be validated using autologous MM-BMM co-culture assays and reverse translated into in vitro screening and in vivo models, which will be subsequently used to develop lead compounds that target myeloma cells within their microenvironment.
The clinical expertise of several oncological divisions, the research experience of academic laboratories and the pharmaceutical know-how of small and medium sized enterprises as well as biotech industry joined their efforts within the OPTATIO consortium to drive this important development and to ensure translation towards clinical trials.
Expected impacts of the project include establishment of better diagnostics, new drug screening approaches for MM and novel personalised therapies based on individual ex vivo phenotyping leading to reduced patient mortality. Since envisaged drug screening methods are applicable to other areas of research and development, the project results will open new markets for industry partners in the fields of drug discovery and pharmaceutical development of products and services for personalized medicine.

Convocatoria de propuestas

FP7-HEALTH-2011-two-stage
Consulte otros proyectos de esta convocatoria

Coordinador

MEDIZINISCHE UNIVERSITAT INNSBRUCK
Dirección
Christoph Probst Platz 1
6020 Innsbruck
Austria

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Wolfgang Willenbacher (Dr.)
Aportación de la UE
€ 510 700

Participantes (11)

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Alemania
Aportación de la UE
€ 287 956,80
Dirección
Josef-schneider-strasse 2
97080 Wurzburg

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Melanie Bauer (Ms.)
Masarykova univerzita
Chequia
Aportación de la UE
€ 279 600
Dirección
Zerotinovo Namesti 9
601 77 Brno

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Sabina Sevcikova (Dr.)
UNIVERSITA DEGLI STUDI DI BARI ALDO MORO
Italia
Aportación de la UE
€ 262 800
Dirección
Piazza Umberto I 1
70121 Bari

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Domenico Ribatti (Prof.)
DEL-PESTI CENTRUMKORHAZ-ORSZAGOS HEMATOLOGIAI ES INFEKTOLOGIAI INTEZET
Hungría
Aportación de la UE
€ 144 000
Dirección
Nagyvarad Ter 1
1097 Budapest

Ver en el mapa

Tipo de actividad
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Contacto administrativo
Tamás Masszi (Dr.)
VEREIN ZUR FOERDERUNG DER KREBSFORSCHUNG IN TIROL
Austria
Aportación de la UE
€ 190 800
Dirección
Innrain 66
6020 Innsbruck

Ver en el mapa

Tipo de actividad
Research Organisations
Contacto administrativo
Richard Greil (Prof.)
KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
Alemania
Aportación de la UE
€ 319 792,50
Dirección
Breisacher Strasse 117
79106 Freiburg

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Michael Kubbutat (Dr.)
VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG
Hungría
Aportación de la UE
€ 239 760
Dirección
Viola Utca 2
8200 Veszprem

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Zoltán Dobai (Mr.)
ONCOTYROL-CENTER FOR PERSONALIZED CANCER MEDICINE GMBH
Austria
Aportación de la UE
€ 293 040
Dirección
Karl Kapferer Strasse 5/3
6020 Innsbruck

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Lukas A. Huber (Prof.)
PHARMA MAR SA
España
Aportación de la UE
€ 239 880
Dirección
Avda De Los Reyes 1 Poligono Industrial La Mina Colmenar Viejo
28770 Madrid

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Elena Calleja (Ms.)
THE BINDING SITE GMBH
Alemania
Aportación de la UE
€ 37 200
Dirección
Robert-bosch-straße 2a
68723 Schwetzingen

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Silvia Kirchner (Dr.)
CENTER OF EXCELLENCE IN MEDICINE AND IT GMBH
Austria
Aportación de la UE
€ 194 000
Dirección
Karl Kapferer Strasse 5
6020 Innsbruck

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Manuela Bock Bartl (Ms.)